- 21 Visits
- 2 Years
- Participants must be 40-80 years of age
- With current or prior physician diagnosis of asthma
- Documented history of COPD for at least 1 year
The purpose of the study is to investigate the efficacy and safety of GSK5784283 (felcorekibart) compared with placebo in participants with moderate to very severe COPD.
Lynn Institute is a leader in introducing new medications to the market through our clinical trials program. Visit our Participation Information page for Frequently Asked Questions, to see current clinical trials listed, and to find out where each trial is being conducted.
Find out More About Our Participation Program
Participation Information